@article{a429e6cffdfa4314bf102f414f3bf313,
title = "Clinical Features and Therapeutic Outcomes in Men with Advanced Prostate Cancer and DNA Mismatch Repair Gene Mutations",
abstract = "Despite aggressive clinicopathological features, mismatch repair (MMR)-mutated advanced prostate cancers are exquisitely responsive to standard and next-generation hormonal therapies, and also demonstrate anecdotal sensitivity to PD-1 inhibitors. Moreover, the presence of certain histological features (Gleason sum 9 or 10, and intraductal carcinoma) should prompt genomic evaluation of MMR deficiency, which is an actionable finding given the Food and Drug Administration's approval of pembrolizumab in this context.",
keywords = "MSH2, MSH6, Microsatellite instability, Mismatch repair, Prostate cancer",
author = "Antonarakis, {Emmanuel S.} and Farah Shaukat and {Isaacsson Velho}, Pedro and Harsimar Kaur and Eugene Shenderov and Pardoll, {Drew M.} and Lotan, {Tamara L.}",
note = "Funding Information: Funding/Support and role of the sponsor : This work was partially supported by National Institutes of Health Cancer Center Support Grant P30 CA006973 (E.S.A. and T.L.L.), Department of Defense grant W81XWH-16-PCRP-CCRSA (E.S.A.), and the Bloomberg-Kimmel Institute for Cancer Immunotherapy (E.S.A., E.S., and D.M.P.). Funding Information: Financial disclosures: Emmanuel S. Antonarakis certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Emmanuel S. Antonarakis is a paid consultant/advisor to Janssen, Astellas, Sanofi, Dendreon, Medivation, ESSA, AstraZeneca, Clovis, and Merck; he has received research funding to his institution from Janssen, Johnson & Johnson, Sanofi, Dendreon, Genentech, Novartis, Tokai, Bristol Myers-Squibb, AstraZeneca, Clovis, and Merck; and he is the co-inventor of a biomarker technology that has been licensed to Qiagen. Tamara L. Lotan is a paid consultant/advisor to Janssen and has received research funding from Ventana/Roche. Publisher Copyright: {\textcopyright} 2018 European Association of Urology Copyright: Copyright 2019 Elsevier B.V., All rights reserved.",
year = "2019",
month = mar,
doi = "10.1016/j.eururo.2018.10.009",
language = "English (US)",
volume = "75",
pages = "378--382",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier",
number = "3",
}